6505--Radiopharmaceutical - Pylarify

Award Notice Posted

Solicitation number
36C24526Q0034
Agency
Awarded
to Progenics Pharmaceuticals Inc.
Set-aside
No set-aside

Opportunity facts

Contract number
36F79725D009336C24526N0180 Federal contract award

Notice details come from SAM.gov. Updated .

About this opportunity

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 5 awarded a contract to Progenics Pharmaceuticals Inc. on January 2, 2026, for the supply of Pylarify (Piflufolastat F-18), a radiopharmaceutical used for diagnosing prostate cancer metastatic disease through PET/CT imaging. The awarded contract value is $1,811,577.44, with an estimated total contract value of $9,057,887.20 across the base period plus four option periods running from January 1, 2026 through December 31, 2030. The VA anticipates requiring approximately 502 units annually to provide diagnostic imaging services to veteran patients, with Progenics Pharmaceuticals designated as the sole source supplier due to being the only authorized manufacturer of this FDA-approved radiopharmaceutical with the specified longer decay half-life advantages for clinical use.

Notice text

Awarded contract 36F79725D009336C24526N0180 to PROGENICS PHARMACEUTICALS INC for 1811577.44 on 2026-01-02.

Files

Similar open opportunities

Opportunity Agency Set-aside Responses due
6505--FY27 Low Energy General Radiopharmaceuticals 36C25027Q0052 See Section 11 of the Cleveland and Kent, Ohio, United States · NAICS 325412 Veterans Integrated Service Network 10 No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity